VNDA Vanda Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VNDA

Price (delayed)

$3.88

Market cap

$234.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.62

Enterprise value

$189.98M

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 18
Relative Valuation: Rel. Valuation: 26
Relative Profitability: Rel. Profitability: 17

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more ...

Highlights
The revenue has increased by 8% YoY and by 6% QoQ
The gross profit has increased by 7% YoY and by 6% from the previous quarter
VNDA's debt has surged by 178% year-on-year but it is down by 5% since the previous quarter
Vanda Pharmaceuticals's equity has shrunk by 57% YoY and by 9% QoQ
VNDA's quick ratio has plunged by 55% YoY and by 7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vandapharma.com
Peers: BMY LLY JNJ NVS

Key stats

What are the main financial stats of VNDA

VNDA stock price

How has the Vanda Pharmaceuticals stock price performed over time
Intraday
2.37%
1 week
-1.52%
1 month
-16.2%
1 year
-10.8%
YTD
-56.01%
QTD
-20.98%

Financial performance

How have Vanda Pharmaceuticals's revenue and profit performed over time
Revenue
$229.28M
Gross profit
$214.57M
Operating income
-$177.91M
Net income
-$274.83M
Gross margin
93.6%
Net margin
-119.9%
The operating income has contracted by 47% YoY but it has grown by 4.2% from the previous quarter
VNDA's operating margin is down by 36% YoY but it is up by 10% QoQ
The revenue has increased by 8% YoY and by 6% QoQ
The gross profit has increased by 7% YoY and by 6% from the previous quarter

Price vs fundamentals

How does VNDA's price correlate with its fundamentals

Growth

What is Vanda Pharmaceuticals's growth rate over time

Valuation

What is Vanda Pharmaceuticals stock price valuation
VNDA P/E details
P/E
N/A
P/B
1.17
P/S
1.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.83
Vanda Pharmaceuticals's equity has shrunk by 57% YoY and by 9% QoQ
VNDA's P/B is 30% above its 5-year quarterly average of 0.9 but 27% below its last 4 quarters average of 1.6
VNDA's P/S is 43% below its last 4 quarters average of 1.8 and 40% below its 5-year quarterly average of 1.7
The revenue has increased by 8% YoY and by 6% QoQ

Efficiency

How efficient is Vanda Pharmaceuticals business performance
The company's return on sales fell by 48% YoY but it rose by 9% QoQ
Vanda Pharmaceuticals's ROIC has decreased by 47% from the previous quarter
Vanda Pharmaceuticals's return on equity has decreased by 26% QoQ
Vanda Pharmaceuticals's ROA has decreased by 13% from the previous quarter

Dividends

What is VNDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VNDA.

Financial health

How did Vanda Pharmaceuticals financials performed over time
The total assets is 110% higher than the total liabilities
VNDA's quick ratio has plunged by 55% YoY and by 7% from the previous quarter
The current ratio has dropped by 51% year-on-year and by 4.3% since the previous quarter
VNDA's debt is 91% smaller than its equity
VNDA's debt has surged by 178% year-on-year but it is down by 5% since the previous quarter
Vanda Pharmaceuticals's equity has shrunk by 57% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.